期刊文献+

TNP方案在头颈部鳞状细胞癌中的疗效探讨

The investigation of effects of TNP in the head and neck squamous cell carcinoma
下载PDF
导出
摘要 目的:比较头颈部鳞状细胞癌(SCCHN)治疗中TNP(紫杉醇+奈达铂+替加氟)与PF(氟尿嘧啶+顺铂)组的近期疗效以及不良反应。方法分析2009年—2014年在襄阳市中心医院接受治疗的SCCHN患者的临床资料。根据治疗方案将患者划分为PF组和TNP组。比较两组患者的一般资料、临床特征、治疗疗效以及治疗不良反应。结果本研究纳入患者54例,其中TNP组和PF组各27例,两组患者的临床资料并无统计学差异(P>0.05);两组患者的肿瘤部位、临床分期及分化程度均无统计学差异(P>0.05);TNP组患者的治疗疗效优于PF组,差异具有统计学意义(χ2=7.864,P=0.048);TNP组患者的胃肠道反应发生率显著低于PF组(χ2=4.854,P=0.028),其余不良反应均无统计学差异(P均>0.05)。结论在SCCHN治疗中,TNP方案疗效优于PF方案,且治疗过程中的胃肠道不良反应发生率更低。 Objective Our retrospective study is aimed to compare the effect and the adverse reaction of TNP(paclitaxel liposome +nedaplatin +tegafur)and PF(fluorouracil +cisplatin)in the treatment of head and neck squamous cell carcinoma(SCCHN).Methods Clinical data of patients with SCCHN received treatment at our hospital from 2009 to 2014 was retrospectively analyzed .Patients were divided into PF group and TNP group according to the treatment prescription .The general data,clinical features,treatment and the adverse reactions of the two groups were compared .Results A total of 54 patients was retrospective analyzed ,including 27 patients in TNP group and 27 in PF group.There was no significant differences in clinical data between the two groups .There was no significant differences in the location of the tumor ,clinical stage and differentiation degree between the two groups.The curative effect of TNP group was significantly ameliorated than the PF group .The incidence of gastro-intestinal reaction in TNP group was obviously lower than in PF group .There was no significant differences in the other adverse reactions .Conclusion In the treatment of SCCHN , TNP regimen is more effective than PF regi-men,and the incidence of gastrointestinal adverse reaction during the treatment is lower .
出处 《实用肿瘤学杂志》 CAS 2014年第6期540-544,共5页 Practical Oncology Journal
关键词 头颈部鳞状细胞癌 新辅助化疗 疗效分析 Head and neck squamous cell carcinoma Neoadjuvant chemotherapy Curative effect analy-sis
  • 相关文献

参考文献12

  • 1Machiels JP, Schmitz S. Molecular - targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab- based therapy [ J ]. Curr Opin Oneol, 2011,23 ( 3 ) : 241 - 248.
  • 2Kikuchi M, Shinohara S, Nakamoto Y, et al. Sequential FDG -PET/CT after neoadjuvant chemotherapy is a predictor of histopathologie response in patients with head and neck squamous cell carcinoma [ J ]. Mol Imaging Biol, 2011,13 (2) :368 -377.
  • 3Yamane T, Kikuchi M, Shinohara S, et al. Reduction of [ ( 18 ) F ] fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma [J]. Mol Imaging Biol,2011,13(2) :227 -231.
  • 4Sato D, Kogashiwa Y, Tsukahara K, et al. Phase I study of nedaplatin prior to S - 1 in patients with locally advanced head and neck squamous cell carcinoma [ J ]. Chemothera- py,2013,59(4) :314 -318.
  • 5李杰.新辅助化疗对进展期乳腺癌患者 CD46表达影响及临床预后预测意义的研究[J].实用肿瘤学杂志,2014,28(2):123-128. 被引量:2
  • 6张乃千,陶维阳,史蓬亮,牛明,庞达.新辅助化疗对乳腺癌分子表型的影响[J].实用肿瘤学杂志,2013,27(2):160-164. 被引量:6
  • 7Kikuchi M, Nakamoto Y, Shinohara S, et al. Early evaluation of neoadjuvant chemotherapy response using FDG - PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma [ J ]. Int J Clin Oncol, 2013, 18 (3) :402 -410.
  • 8Zhang XR, Liu ZM, Liu XK, et al. Influence of pathologic complete response to neoadjuvant chemotherapy on long - term survival of patients with advanced head and neck squa- mous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol O-ral Radio1,2013,115 (2) :218 - 223.
  • 9邱杰,张文伟,彭诗东.头颈癌的治疗进展[J].实用肿瘤学杂志,2002,16(3):240-240. 被引量:1
  • 10方凤琴,黄金颖,刘文中,董慧蕾,李奕.头颈鳞癌p53、Bcl-2及P-gp表达在治疗中的作用[J].实用肿瘤学杂志,2007,21(6):516-518. 被引量:3

二级参考文献33

  • 1赵健,吴一龙,王远东,赵光日,王建.新辅助化疗对乳腺癌雌、孕激素受体和HER-2的影响[J].第一军医大学学报,2004,24(12):1437-1439. 被引量:9
  • 2长谷川正俊.化学放射线疗法の分子生物学.血液·肿瘤科,2000,40:72-78.
  • 3漆崎一朗.アボト-シスの诱导[J].综合临床,2001,50:155-159
  • 4田中信之.p53にょる细胞死分子机构[J].实验医学,2002,18:1793-1797
  • 5Chada S, Mhashilkar A, Roth JA. et al. Development of vaccines against self-antigens: the p53 paradigm[J]. Curr Opin Drug Discov Devel, 2003:6:169-173
  • 6Anderson SC, Johnon DE, Harris MP, et al. p53 gene therapy in a rat model of hepatocellualar carcinoma:intro-arterial delivery of a recombinant abenvirus[J]. Clin Cancer Res, 1998;7:1649-1659
  • 7Adriano P, Corrado R, Massimiliano F, et al. Prevalence of p53, bcl-2, and Ki-67 Immunoreactivity and of Apoptosis in Normal Oral Epithelium and in Premalignant and Malignant Lesions of the Oral Cavity[J]. Oral Maxillofac Surg, 2002; 60: 532-540
  • 8家根旦有.下咽头癌及び甲状腺癌にぉけるp53遗传异常とその意义[J].头颈部肿瘤,1997,23:589-594
  • 9Oakss SA, Opferman JT, Pozzan T, et al. Regulation of endoplasmic reticulum Ca^2+ dynamics by pyoapoptotic Bcl-2 family members[J]. Biochem Pharmacol, 2003 ; 66:1335-1340
  • 10川崎雅之.p53遗传异常药剂耐性[J].医学のぁゅみ,2001,199:651-654

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部